氟达拉滨联合米托蒽醌与CHOP方案治疗恶性淋巴瘤的疗效及安全性

目的评价氟达拉滨联合米托蒽醌与CHOP方案治疗恶性淋巴瘤的疗效和安全性。方法 2010年2～11月收治经组织学确诊的恶性淋巴瘤40例患者,随机分为观察组及对照组,各20例,观察组接受含FND化疗,其中惰性淋巴瘤患者11例,复发的进展性淋巴瘤患者9例;对照组接受CHOP联合方案化疗,其中惰性淋巴瘤患者12例,复发的进展性淋巴瘤患者8例。结果观察组接受FND化疗的淋巴瘤患者有效率为90.0%,完全缓解率为60.0%,对照组接受CHOP方案化疗的淋巴瘤患者有效率为55.0%,完全缓解率为15.0%;观察组主要不良反应为骨髓抑制,有65.0%周期发生Ⅲ/Ⅳ度中性粒细胞减少,发生肺部感染3例;对照组无Ⅳ度中性粒细胞减少,仅20.0%周期发生Ⅲ度中性粒细胞减少,其他不良反应均为轻度,以消化道反应为主。结论含氟达拉滨联合米托蒽醌方案,对于恶性淋巴瘤患者具有肯定的疗效,不良反应可以耐受。

Clinical study of fludarabine plus mitoxantrone combination chemotherapy and CHOP chemotherapy for lymphoma malignant neoplasm patients

Objective To study the efficacy and the safety of fludarabine plus mitoxantrone combination chemotherapy and CHOP chemotherapy for lymphoma malignant neoplasm patients. Methods From February 2010 to November 2010,fourty patients with pathologically confirmed lymphoma malignant neoplasm were included into the study, were divided into observing group and control group,each has twenty patients. Observing group with fludarabine plus mitoxantrone combination chemotherapy,eleven of the patients were indolent lymphoma, nine were relapsed aggressive lymphoma,control group with CHOP chemotherapy, twelve of the patients were indolent lymphoma,eight were relapsed aggressive lymphoma. Results The overall response rate of patients receiving FND was 90.0%,with 60.0% complete response.The overall response rate of patients receiving CHOP was 55.0%,with 15.0% complete response.The major side effect of observing group was myelosuppression,grade Ⅲ to Ⅳ neutropenia occurred in 69.5%,and pneumonia was seen in grade Ⅲ patients. Grade Ⅳ neutropenia occurred and grade Ⅲ in 22.2% by CHOP. Non hematological side effects were mild and consisted mainly of nausea and vomiting. Conclusion Fludarabine plus mitoxantrone combination chemotherapy is effective and well tolerated for lymphoma malignant neoplasm patients.